American journal of clinical oncology · 2019
The Effect of Metformin on Prognosis in Patients With Locally Advanced Gastric Cancer Associated With Type 2 Diabetes Mellitus.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seo Ho Seok, Jung Yoon Ju, Kim Ji Hyun, Lee Han Hong, Park Cho Hyun
Аннотация
OBJECTIVES: This study examined the effect of metformin use on the prognosis of gastric cancer patients.
MATERIALS AND METHODS: The study population comprised 2187 patients who underwent curative gastrectomy for the treatment of gastric cancer. They were divided into 3 groups: metformin (n=103), non-metformin (n=139), and non-diabetes mellitus (DM) (n=1945) according to their history of type 2 DM and metformin use. Survival, disease recurrence, and the pathologic stage were analyzed.
RESULTS: Overall survival was better in the metformin group than in the non-DM group (P=0.005). Metformin use was an independent prognostic factor of overall survival, cancer recurrence, and peritoneal recurrence. An effect of metformin use was especially notable in patients with T4 or N0 disease.
CONCLUSIONS: Metformin improves the survival of patients with gastric cancer and type 2 DM.
MATERIALS AND METHODS: The study population comprised 2187 patients who underwent curative gastrectomy for the treatment of gastric cancer. They were divided into 3 groups: metformin (n=103), non-metformin (n=139), and non-diabetes mellitus (DM) (n=1945) according to their history of type 2 DM and metformin use. Survival, disease recurrence, and the pathologic stage were analyzed.
RESULTS: Overall survival was better in the metformin group than in the non-DM group (P=0.005). Metformin use was an independent prognostic factor of overall survival, cancer recurrence, and peritoneal recurrence. An effect of metformin use was especially notable in patients with T4 or N0 disease.
CONCLUSIONS: Metformin improves the survival of patients with gastric cancer and type 2 DM.
Предметные рубрики MeSH
AdultAgedCause of DeathCohort StudiesComorbidityDatabases, FactualDiabetes Mellitus, Type 2Disease-Free SurvivalFemaleGastrectomyHumansHypoglycemic AgentsKaplan-Meier EstimateMaleMetforminMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisProportional Hazards ModelsRepublic of KoreaRetrospective StudiesStomach NeoplasmsSurvival Analysis